Treatment of Dyspnea in Aortic Regurgitation

Introduction to Aortic Regurgitation Management

The European Society of Cardiology recommends urgent surgical aortic valve replacement for symptomatic patients with dyspnea from aortic regurgitation, as symptoms herald left ventricular decompensation and mortality increases dramatically once symptoms develop 1, 2, 3

The European Society of Cardiology suggests that medical therapy serves only as a temporizing bridge to emergency surgery and should never delay surgical intervention 1
Vasodilators, such as sodium nitroprusside or intravenous nitroglycerin, should be administered immediately to reduce left ventricular afterload and improve forward flow in patients with acute severe aortic regurgitation 1
Beta-blockers are contraindicated in acute aortic regurgitation as they prolong diastole and increase regurgitant volume, according to the American College of Cardiology 4

Surgery is indicated for all symptomatic patients with severe aortic regurgitation regardless of left ventricular function, as mortality reaches 10-25% once symptoms occur, according to the European Society of Cardiology 1, 2, 3
The American College of Cardiology recommends ACE inhibitors or dihydropyridine calcium channel blockers, such as nifedipine, for blood pressure control and afterload reduction in patients with chronic symptomatic aortic regurgitation 4
Target systolic blood pressure should be maintained below 140 mmHg to reduce left ventricular wall stress in patients with chronic symptomatic aortic regurgitation 5

The European Society of Cardiology indicates that surgery is indicated when left ventricular ejection fraction falls to ≤50-55% or left ventricular end-systolic diameter reaches ≥50 mm (or 25 mm/m²) in asymptomatic patients with severe aortic regurgitation 1
Vasodilators, such as nifedipine 30-90 mg daily or ACE inhibitors, may prolong the compensated phase and delay need for surgery in asymptomatic patients with normal left ventricular function, according to the American College of Cardiology 4

Echocardiography should be performed every 6-12 months in asymptomatic severe aortic regurgitation to monitor for left ventricular dysfunction or progressive dilatation, as recommended by the European Society of Cardiology 1, 6
More frequent monitoring (every 3-6 months) is warranted if left ventricular ejection fraction begins declining or end-systolic dimensions increase in patients with asymptomatic severe aortic regurgitation 5

Never delay surgery in symptomatic patients to "optimize" medical therapy—symptoms indicate decompensation and mortality risk increases substantially, according to the European Society of Cardiology 1, 2, 3
Do not use beta-blockers for rate control or blood pressure management in aortic regurgitation, as they worsen hemodynamics by prolonging diastole, as stated by the American College of Cardiology 4, 5
Avoid aggressive diuresis in patients with small left ventricular chambers, as preload reduction can compromise cardiac output, according to the American College of Cardiology 4